ClinicalTrials.gg
CompletedNCT05398848Updated Feb 29, 2024

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

A Phase 3 interventional study of Recombinant two-component COVID-19 vaccine (CHO cell) and Placebo in COVID-19, sponsored by Jiangsu Rec-Biotechnology Co., Ltd.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Jiangsu Rec-Biotechnology Co., Ltd. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,623
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.

Enrollment
3rd of 18
7,623 · median 714
Started
2022
with 6 others
Phase 3
7 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
4 of 18
Jiangsu Rec-Biotechnology Co., Ltd.

Among the 18 studies testing CHO cell in COVID-19, this one is the 3rd largest by enrollment, is one of 7 that started in 2022, is one of 7 in phase 3, and was the 15th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About CHO cell

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing CHO cell in COVID-19, or all of them as a file.
02

Study summary

This is a multicenter designed Phase III clinical trial. About 10000 participants plan to be enrolled.The objectives of this study are to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19 vaccine (CHO cell) in adults

Read the detailed description

This study is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical trial. The objectives are to evaluate the efficacy, safety, and immunogenicity of ReCOV in adults aged 18 years and older who have not received any COVID-19 vaccination, and have no history of known COVID-19 in previous 6 months. Three-dose intramuscular (IM) vaccination schedule (21 days interval) will be applied.

About 10000 participants (about 15% participants ≥ 60 years old) with SARS-CoV-2 antibody (IgM and IgG) negative at baseline, will be randomized in a ratio of 1:1 to receive ReCOV (20 μg) or placebo on Day 0, Day 21, and Day 42, respectively. Participants will be stratified by age (18-59 years, ≥ 60 years) and study sites (if applicable).

For efficacy visits, study staff will contact participants on a weekly basis to remind reporting any signs or symptoms of COVID-19. If participants report any signs or symptoms that may be related to COVID-19, they will be required to immediately conduct an unscheduled visit under the instruction by site staff for COVID-19 related assessment and receiving treatment as deemed appropriate.

For reactogenicity and safety visits, all vaccinated participants will be observed for 30 minutes after each dose vaccination at study site for solicited or unsolicited AEs, and will be given subject diary to record solicited AEs within 7 days after each vaccination, and unsolicited AEs from the 1st vaccination to 28 days after the 3rd vaccination.

Approximately 600 participants will be included in the immunogenicity subgroup. Except for the efficacy and safety follow-up visits described above, this subgroup will be collected blood sample on Day 0 (pre-vaccination) and 14 days (+3 days), 90 days (±15 days) and 6 months (±15 days) after the 3rd dose.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years and older.
  2. Able and willing to comply with all study requirements.
  3. Willing to allow investigators to discuss the medical history with his/her general practitioner/personal doctors and access all medical records which are relevant to study procedures.
  4. Healthy adults, or adults with stable medical condition who have a pre-existing medical condition that does not meet any exclusion criteria. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
  5. For females of only, willing to practice continuous effective until 90 days after the final dose vaccination, and have negative pregnancy tests before each dose vaccination.

    • Nonchildbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or . A follicle-stimulating hormone (FSH) level and the amenorrhea duration (e.g. amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause) may be measured at the discretion of investigator to confirm postmenopausal status.
    • The effective contraceptive methods include sexual abstinence or adequate contraceptive measures such as intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, condoms (male), diaphragm, and cervical cap, etc.
  6. Males participating in this study who are involved in heterosexual sexual activity must agree to practice adequate contraception (as described above) and refrain from donating sperm until 90 days after receiving the final dose vaccination.
  7. Agreement to refrain from blood donation during the study.
  8. Provide written form (ICF) prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Laboratory confirmed SARS-CoV-2 infection defined by RT-PCR assay at screening. Participants with negative result for rapid antigen testing can be enrolled before having the result of RT-PCR assay, however, the participant needs to be withdrawn the following vaccination if the RT-PCR result shows positive.
  2. SARS-CoV-2 antibodies (IgM or IgG) positive at screening.
  3. Medical history of severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and COVID-19 within 6 months prior to the randomization.
  4. Fever (oral temperature ≥ 37.5°C / axillary temperature ≥ 37.3°C) on the day of vaccination or within recent 72 hours.
  5. History of severe allergic disease or reactions likely to be exacerbated by any component of ReCOV, such as allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopaenic purpura, local hypersensitive necrosis reaction (Arthus reaction), or prior history of serious adverse reaction to any vaccine or drug, such as allergy, urticaria eczema, dyspnea, and angioneurotic edema.
  6. Have malignant tumor (except for skin basal cell carcinoma or carcinoma uterine cervix in situ) and immune disease (e.g., documented [HIV] infection, systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy, and other immune disease that may influence immune response at investigator's discretion).
  7. Have other severe and/or uncontrolled conditions, including but not limited to, acute infectious disease, cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, hematology disease, endocrine disorder, psychiatric condition and neurological illness. Uncontrolled condition is defined as significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
  8. Have bleeding disorder (e.g. factor deficiency, coagulopathy or disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
  9. Received or other immunomodulators, antiallergic therapy, or cytotoxicity therapy for 14 or more consecutive days within 6 months before receiving the product (IP). Local administration of immunosuppressant or immunomodulator is allowed (e.g., ointment, eye drops, inhalation, or nasal spray). Drugs for local administration should not be given at a dose over the recommended level in package insert or participants should have no signs of systemic exposure.
  10. Administration of immunoglobulin and/or blood product within 3 months before using the IP or plan to use that during the study.
  11. Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e., warfarin) or novel oral anticoagulants (i.e., apixaban, rivaroxaban, dabigatran and edoxaban).
  12. Used other investigational drug or interventional device within 1 month before using the IP or plan to use that during the study, or are using other investigational drug or are within 5 half-lives after the last dose of the investigational drug.
  13. Used subunit or inactivated vaccine within 14 days before using the IP, or used attenuated live or mRNA vaccine within 1 months (30 days) before using the IP, or plan to receive any other vaccines (except for the seasonal influenza vaccine, or emergency use authorized vaccines) during the study.
  14. Prior receipt of an investigational or licensed COVID-19 vaccine, or investigational or approved vaccine against a coronavirus, including but not limited to SARS-CoV-1 and MERS-CoV.
  15. Suspected or known current alcohol or drug dependency.
  16. Pregnancy, lactation or willingness/intention to become pregnant within 90 days after receiving the last dose of study vaccine.
  17. Staff of study site, the sponsor, and contract research organization (CRO) taking part in study conduct.
  18. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data at investigator's discretion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,623 participants (actual)

Study arms

  • Experimental
    Recombinant two-component COVID-19 vaccine (CHO cell)

    Antigen: NTD-RBD-foldon protein, Adjuvant (BFA03)

    Biological: Recombinant two-component COVID-19 vaccine (CHO cell)

  • Placebo comparator
    Placebo

    Adjuvant (BFA03)

    Biological: Placebo

Interventions

  • Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

  • BiologicalPlacebo

    Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of ReCOV in preventing Reverse Transcription-Polymerase Chain Reaction (RT-PCR) confirmed symptomatic COVID-19 in adults

    RT-PCR confirmed symptomatic COVID-19 cases (regardless of severity) that occurred \> 14 days after 3 doses vaccination.

    Time frame: > 14 days after 3 doses vaccination.

Secondary outcomes

  1. Evaluate the safety and reactogenicity

    The occurrence of solicited local and systemic adverse events (AEs) within 7 days after each vaccination.

    Time frame: within 7 days after each vaccination

  2. Evaluate the safety and reactogenicity

    The occurrence of unsolicited AEs from the 1st dose to 28 days after the 3rd vaccination

    Time frame: from the 1st dose to 28 days after the 3rd vaccination.

  3. Evaluate the safety and reactogenicity

    The occurrence of serious adverse events (SAEs) and adverse events of special interest (AESIs) from the 1st dose to the end of study.

    Time frame: from the 1st dose to the end of study.

  4. To evaluate the efficacy of ReCOV in preventing RT-PCR confirmed symptomatic COVID-19 with various severity in adults

    RT-PCR confirmed moderate, severe, critical COVID -19, or death that occurred \> 14 days after 3 doses vaccination

    Time frame: > 14 days after 3 doses vaccination.

  5. To evaluate the efficacy of ReCOV in preventing RT-PCR confirmed symptomatic COVID-19 with various severity in adults

    RT-PCR confirmed severe, critical COVID-19, or death that occurred \> 14 days after 3 doses vaccination.

    Time frame: > 14 days after 3 doses vaccination.

  6. To evaluate the efficacy of ReCOV in preventing RT-PCR confirmed symptomatic COVID-19 with various severity in adults

    RT-PCR confirmed symptomatic COVID-19 cases (regardless of severity) that occurred \> 14 days after 3 doses vaccination in different age groups (18-59 years and ≥ 60 years ).

    Time frame: > 14 days after 3 doses vaccination in different age groups (18-59 years and ≥ 60 years ).

  7. To evaluate the immunogenicity of ReCOV

    The seroconversion rate (SCR), geometric mean titer (GMT) and geometric mean increase (GMI) of neutralizing antibody against prototype and epidemic strain at 14 days, 3 months and 6 months after 3 doses vaccination.

    Time frame: at 14 days, 3 months and 6 months after 3 doses vaccination

  8. To compare the immunogenicity of ReCOV between Asian and Non-Asian in the immunogenicity subgroup

    The SCR and GMT of neutralizing antibody against prototype at 14 days,3 months and 6 months after 3 doses vaccination.

    Time frame: at 14 days,3 months and 6 months after 3 doses vaccination

  9. Genotyping of SARS-CoV-2 virus nucleic acid sequence of COVID-19 cases to evaluate the possible viral mutations

    SARS-CoV-2 virus nucleic acid sequence of RT-PCR confirmed symptomatic COVID-19 cases that occurred \>14 days after 3 doses vaccination derived from isolates or direct nasopharyngeal (NP) (preferred)/ oropharyngeal (OP) swab, or respiratory samples (including saliva samples, or bronchoalveolar lavage fluid, if applicable).

    Time frame: >14 days after 3 doses vaccination

Other outcomes

  1. Exploratory :

    To evaluate the efficacy of ReCOV after the first dose vaccination in preventing RT-PCR confirmed symptomatic COVID-19 in adults aged 18 years and older.

    Time frame: > 14 days after the first dose vaccination

07

Study locations

11 sites
  • B.P. Koirala Institute of Health Sciences
    Dharān Bāzār, Nepal
  • Aramil City Hospital
    Aramil, Russian Federation
  • LLC Medical Service solutions
    Izhevsk, Russian Federation
  • 'Federal State Budgetary Scientific Institution "Russian Scientific Centre of Surgery named after academician B.V. Petrovsky"
    Moscow, Russian Federation
  • 'Joint Stock Company "Clinical and diagnostic center "Euromedservice"
    Moscow, Russian Federation
  • State Regional Budgetary Institution of Healthcare "Murmansk Regional Clinical Hospital named after P.A. Bayandin"
    Murmansk, Russian Federation
  • LLC Professorskaya klinika
    Perm, Russian Federation
  • UZI 4D Clinic LLC
    Pyatigorsk, Russian Federation
  • Klinika Zvyezdnaya LLC
    Saint Petersburg, Russian Federation
  • Limited Liability Company "Sfera-Med"
    Saint Petersburg, Russian Federation
  • Research Center Eco-safety
    Saint Petersburg, Russian Federation
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make individual participant data (IPD) available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2023, 10 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 10 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 1, 2022
StartActual
Oct 31, 2022
Primary completionActual
Sep 4, 2023
CompletionActual
Dec 29, 2023
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05398848
Lead sponsor
Jiangsu Rec-Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Oct 31, 2022
Primary completion
Sep 4, 2023
Completion
Dec 29, 2023
Last update
Feb 29, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion